Newsfeeds - Spark Newswire

2 minute read

Looking Into Aileron Therapeutics’s Recent Short Interest

Today, 2:36 AM

Aileron Therapeutics's (NASDAQ:ALRN) short percent of float has risen 50.0% since its last report. The company recently reported that it has 30 thousand shares sold short, which is 0.84% of all regular shares that are available for trading.

ALRN

3 minute read

S&P 500 Down 2%; Mobilicom Shares Spike Higher

By Lisa Levin

Today, 2:36 AM

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P 500 also fell, dropping, 2.05% to 3,995.66.

ALRN

4 minute read

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 2:36 AM

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

AKAN

1 minute read

Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall

By Vandana Singh

Today, 2:36 AM

Aileron Therapeutics (NASDAQ:ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast…

ALRN

3 minute read

Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February

By Lisa Levin

Today, 2:36 AM

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday. The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P 500 also fell, dropping, 1.65% to 4,011.67.

ALRN

3 minute read

Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast

By Lisa Levin

Today, 2:36 AM

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ fell 1.24% to 11,640.85. The S&P 500 also fell, dropping, 1.03% to 4,037.11.

ALRN

1 minute read

Aileron Therapeutics Announces Termination Of Phase 1b Breast Cancer Chemoprotection Trial And Exploration Of Strategic Alternatives

By Bill Haddad

Today, 2:36 AM

Aileron Therapeutics (NASDAQ:ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial

ALRN

16 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 2:36 AM

On Wednesday, 258 companies hit new 52-week lows.

ACB

1 minute read

Aileron Therapeutics Presents Results From Phase 1 Study In Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest On Bone Marrow Stem Cells And Hair Follicles At EORTC-NCI-AACR International Conference

By Benzinga Newsdesk

Today, 2:36 AM

p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) Study showed

ALRN

1 minute read

Aileron Therapeutics Announces Oral Presentation Of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles And Their Stem Cells From Chemotherapy-Induced Damage At The European Society For Dermatological Research Annual Meeting 2022

By Benzinga Newsdesk

Today, 2:36 AM

New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May

ALRN